JM ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	6
13	Multiple sclerosis/Neuromyelitis optica	1

6. Parkinson disease

Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04377945 (ClinicalTrials.gov)	April 28, 2021	4/5/2020	Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components	A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components	Dyskinesias;Parkinson Disease	Drug: Part 1, JM-010 component Group A;Drug: Part 1, JM-010 component Group B;Drug: Part 1, JM-010 component Group C;Drug: Part 1, Placebo Group;Drug: Part 2, JM-010 combination Group A;Drug: Part 2, JM-010 combination Group B;Drug: Part 2, JM-010 component Group C;Drug: Part 2, Placebo Group	Bukwang Pharmaceutical	NULL	Recruiting	18 Years	80 Years	All	188	Phase 2	United States
2	EUCTR2017-003415-19-IT (EUCTR)	10/03/2020	19/05/2021	A Clinical Study in Parkinson’s Disease Patients With Moderate to Severe Abnormal Movements to See If JM-010 is Effective and Safe/Tolerable.	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations of JM-010	Parkinson’s Disease Patients With Moderate to Severe Dyskinesia MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: JM-010 Product Code: JM-010 INN or Proposed INN: Buspirone hydrochloride INN or Proposed INN: Zolmitriptan Product Name: JM-010 Product Code: JM-010 INN or Proposed INN: Buspirone hydrochloride INN or Proposed INN: Zolmitriptan	Contera Pharma	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	81	Phase 2	France;Spain;Germany;Italy
3	NCT03956979 (ClinicalTrials.gov)	July 22, 2019	17/5/2019	A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson's Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations of JM-010	Dyskinesias	Drug: JM-010 group A;Drug: JM-010 group B;Drug: Placebos	Contera Pharma	Bukwang Pharmaceutical	Recruiting	18 Years	80 Years	All	81	Phase 2	France;Germany;Italy;Spain
4	EUCTR2017-003415-19-ES (EUCTR)	31/10/2018	20/08/2018	A Clinical Study in Parkinson’s Disease Patients With Moderate to Severe Abnormal Movements to See If JM-010 is Effective and Safe/Tolerable.	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations Of JM-010	Parkinson’s Disease Patients With Moderate to Severe Dyskinesia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: JM-010 Product Code: JM-010 INN or Proposed INN: Buspirone hydrochloride INN or Proposed INN: Zolmitriptan Product Name: JM-010 Product Code: JM-010 INN or Proposed INN: Buspirone hydrochloride INN or Proposed INN: Zolmitriptan	Contera Pharma	NULL	Not Recruiting			Female: yes Male: yes	81	Phase 2	France;Spain;Germany
5	JPRN-JMA-IIA00385	01/08/2018	12/09/2018	Kyoto Trial to Evaluate the Safety and Efficacy of iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease	Kyoto Trial to Evaluate the Safety and Efficacy of iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease	Parkinson's disease	Intervention type:DRUG. Intervention1:TACROLIMUS TABLETS, Dose form:TABLET, Route of administration:ORAL, intended dose regimen:In the early phase, the immunosuppressant is orally administered 0.03 to 0.15 mg/kg, twice a day, and the targeted blood concentration is within a range of 5-10 ng/mL as a trough value..	Kyoto University Hospital	NULL	Completed	>=50 YEARS	<70 YEARS	BOTH	7	Phase 3	Japan
6	NCT02439203 (ClinicalTrials.gov)	May 2015	30/4/2015	Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia	A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study in Subjects With Parkinson's Disease With Moderate to Severe Levodopa-induced Dyskinesia, to Assess the Efficacy, Safety/Tolerability and Pharmacokinetics of JM-010	Parkinson's Disease;Levodopa Induced Dyskinesia (LID)	Drug: JM-010;Drug: Placebo	Bukwang Pharmaceutical	Contera Pharma ApS	Completed	18 Years	N/A	Both	30	Phase 2	South Africa

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03887065 (ClinicalTrials.gov)	June 15, 2019	10/3/2019	Magnetic Resonance Imaging Study of JM-4 in Multiple Sclerosis/Clinically Patients	Magnetic Resonance Imaging 12 Day Study for Multiple Sclerosis/Clinically Isolated Syndrome Trial of JM-4 Novel Human Peptide	Multiple Sclerosis	Drug: JM-4	Cook, Stuart, MD	NULL	Not yet recruiting	18 Years	55 Years	All	15	Early Phase 1	NULL